Compounds of Formula I are disclosed ##STR00001## As well as pharmaceutically acceptable salts thereof. Methods of using said compounds and pharmaceutical compositions containing said compounds are also disclosed.

Hepatitis C virus inhibitors having the general formula (I) ##STR00001##
are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

The invention relates to compounds of Formula I:

##STR00001##

and pharmaceutically acceptable salts and prodrugs thereof, wherein R.sub.1, R.sub.2, and R.sub.3 are defined as set forth in the specification. The compounds are agonists of neurotrophin (such as nerve growth factor) receptors.

Hepatitis C virus inhibitors are disclosed having the general formula: ##STR00001## wherein R.sub.1, R.sub.2, R.sub.3, R, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

The present invention relates to prodrugs of protease inhibitors, such as inhibitors of the proteosome, DPP IV, FAP and the like. Thesepro-inhibitors are activated, i.e., cleaved, by an activated protease to release an active inhibitor moiety in proximity to a target protease. The identity of activating protease and target protease can be the same (such as pro-inhibitors being referred to as Target-Activated Smart Protease Inhibitors or TASPI) or different (e.g., Target-Directed Smart Protease Inhibitors or TDSPI). After activation of the pro-inhibitor, the active inhibitor moiety can self-inactivate by, e.g., intramolecular-cyclization or cis-trans isomerization.

The invention provided herein presents a novel family of antifouling agents based on hydroxylated and fluorinated compounds.

The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof:

##STR00001##

which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Granzyme B inhibitor compounds, compositions that include the compounds, and methods for using the compounds. The compounds of the invention have advantageous water solubility and effectively inhibit Granzyme B.

Compounds, compositions and methods for preventing, treating or curing a coronavirus, picornavirus, and/or hepeviridae virus infection in human subjects or other animal hosts. Specific viruses that can be treated include enteroviruses. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient co-infected with two or more of these viruses, or a combination of one or more of these viruses and norovirus.

The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern as shown in any one of FIGS. 1-4.